Reason for request
Inclusion of the list of medicines reimbursed by National Insurance and approved for use by hospitals. .
Clinical Benefit
| Substantial |
The actual benefit of these drugs is substantial. |
Clinical Added Value
| minor |
INOVELON offers a minor (level IV) improvement in actual benefit in the therapeutic management of patients aged 4 and over with Lennox-Gastaut syndrome that is resistant to first-line treatments. |
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
fQxeXgrGDjb3knPK
